Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.

Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
复制标题

DOI:
10.1084/jem.20052242
复制
发表时间:
2006-02-20
影响因子:
15.3
通讯作者:
Tenen, DG
Tenen, DG
中科院分区:
医学1区
文献类型:
--
作者:
Radomska, HS;Bassères, DS;Zheng, R;Zhang, P;Dayaram, T;Yamamoto, Y;Sternberg, DW;Lokker, N;Giese, NA;Bohlander, SK;Schnittger, S;Delmotte, MH;Davis, RJ;Small, D;Hiddemann, W;Gilliland, DG;Tenen, DG

文献摘要

参考文献

被引文献

相似文献

在约30%的急性髓性白血病(AML)患者中检测到组成性激活FLT 3激酶的突变,并影响下游通路,如细胞外信号调节激酶(ERK)1/2。我们发现FLT 3在人AML中的激活通过ERK 1/2介导的磷酸化抑制CCAAT/增强子结合蛋白α(C/EBPα)的功能,这可能解释白血病母细胞的分化阻滞。在MV 4;11细胞中,FLT 3或MEK 1的药理学抑制导致粒细胞分化。当丝氨酸21位突变为丙氨酸(S21 A)的C/EBPα稳定表达时,也观察到MV 4;11细胞的分化。相比之下,当丝氨酸21突变为天冬氨酸(S21 D)时,没有影响,这模拟了C/EBPα的磷酸化。因此,我们的研究结果表明,靶向MEK/ERK级联反应的治疗或基于组成型活性C/EBPα转导的蛋白质治疗的开发可能证明在治疗对FLT 3抑制剂治疗耐药的FLT 3突变型白血病中有效。
Mutations constitutively activating FLT3 kinase are detected in ∼30% of acute myelogenous leukemia (AML) patients and affect downstream pathways such as extracellular signal–regulated kinase (ERK)1/2. We found that activation of FLT3 in human AML inhibits CCAAT/enhancer binding protein α (C/EBPα) function by ERK1/2-mediated phosphorylation, which may explain the differentiation block of leukemic blasts. In MV4;11 cells, pharmacological inhibition of either FLT3 or MEK1 leads to granulocytic differentiation. Differentiation of MV4;11 cells was also observed when C/EBPα mutated at serine 21 to alanine (S21A) was stably expressed. In contrast, there was no effect when serine 21 was mutated to aspartate (S21D), which mimics phosphorylation of C/EBPα. Thus, our results suggest that therapies targeting the MEK/ERK cascade or development of protein therapies based on transduction of constitutively active C/EBPα may prove effective in treatment of FLT3 mutant leukemias resistant to the FLT3 inhibitor therapies.
DOI: 10.1182/blood-2003-02-0479
发表时间: 2003-11-01
期刊: BLOOD
影响因子: 20.3
作者:
D'Alo, F;Johansen, LM;Tenen, DG
通讯作者: Tenen, DG
DOI: 10.1073/pnas.0404731101
发表时间: 2004-09-07
影响因子: 11.1
作者:
Helbling, D;Mueller, BU;Pabst, T
通讯作者: Pabst, T
DOI: 10.1038/sj.leu.2402805
发表时间: 2003-02-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Kaeferstein, A;Krug, U;Verbeek, W
通讯作者: Verbeek, W
DOI: 10.1016/s1535-6108(02)00070-3
发表时间: 2002-06-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Kelly, LM;Yu, JC;Giese, NA
通讯作者: Giese, NA